Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Prockop, S., Mahadeo, K. M., Beitinjaneh, A., Choquet, S., Stiff, P., Reshef, R., Satyanarayana, G., Dahiya, S., Parmar, H., Ye, W., Gamelin, L., & Dinavahi, R. (2021). Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 138(Supplement 1), 301–301. https://doi.org/10.1182/blood-2021-147274

Authors:

Susan E. Prockop

Kris M. Mahadeo

Amer Beitinjaneh

Sylvain Choquet

Patrick J. Stiff

Ran Reshef

Gowri Satyanarayana

Saurabh Dahiya

Hema Parmar

Wei Ye

Laurence Gamelin